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Significance of Genetic Abnormalities of p53 Protein in Slovenian Patients 
with Gastric Carcinoma
Aim To analyze genetic alterations of p53 gene in Slovenian gastric can-
cer patients and to compare these alterations with clinicopathological 
parameters in order to assess the value of p53 as a prognostic factor.
Methods We analyzed the samples from 230 Slovenian patients with gas-
tric cancer, collected between 1983 and 2001. p53 expression was evalu-
ated immunohistochemically with DO-7 monoclonal antibody. In addi-
tion, loss of heterozigosity (LOH) and microsatellite instability (MSI) of 
p53 gene were evaluated, as well as its mutational status in the selected 
population of patients.
Results p53 expression was associated with poorer survival and it was 
an independent predictor in multivariate analysis, along with TNM (T 
– size of tumor, N – nodal involvement, M – distant metastasis) stage 
status. Loss of heterozigosity and microsatellite instability status did not 
influence survival, however we found association of loss of heterozigosity 
with Lauren’s (Mantel-Haenszel test, P = 0.004) and Ming’s (Mantel-
Haenszel test, P<0.001) classification, whereas microsatellite instabil-
ity was associated with gender (Mantel-Haenszel test, P =0 .017), TNM 
stage (χ2 test, P =0 .006) of gastric cancer, and lymph node involvement 
(pN) (χ2 test, P =0 .004).
Conclusions The data on p53 abnormalities, when considered separate-
ly, could be of relative value for predicting the behavior of gastric tumors. 
However, our analyses showed that studying p53 overexpression, loss of 
heterozigosity, microsatellite instability, and mutational analysis could 
provide data that, particularly in combination with some clinicopatho-
logical features, might be of clinical value for predicting the tumor behav-
ior and patient response to therapy.
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In the 1980s, stomach cancer was the most fre-
quent type of cancer worldwide and, although 
its incidence has gradually declined in devel-
oped countries, it still remains one of the leading 
causes of mortality worldwide, with a modest 5-
year survival of about 25% (1,2). In general, it is 
still the one of the leading cause of cancer-relat-
ed death, surpassed only by lung and breast can-
cer (3,4).
According to the classification by Lauren (5), 
stomach cancer is classified into two main his-
tological types: diffuse and intestinal. Particular 
combinations of genetic and epigenetic changes 
differ in both subtypes, although a few of them 
appear to be common, as shown by several stud-
ies in the last decade (6-8). Namely, a significant 
proportion of intestinal type carcinomas progress 
to diffuse types, and in individuals a large num-
ber of tumors could also be comprised of a mix-
ture of both cellular subtypes (9,10). In addition 
to hypermethylation of several genes and loss of 
heterozigosity, abnormalities of p53 tumor sup-
pressor gene are the most evident genetic changes 
found in both types of gastric cancer, which is in 
accordance with generally accepted opinion that 
genetic changes of p53 are one of the most preva-
lent alterations in human cancers (8,10,11). The 
main mechanisms of inactivation in gastric can-
cer are loss of heterozigosity, mutations, and frame 
shift deletions (8,9). These abnormalities occur in 
46.6 to 74% of gastric cancers, regardless of the 
histological subtype. They are also frequently ob-
served in pre-cancerous lesions such as intestinal 
metaplasia and dysplasia, which are precursors of 
the intestinal type of gastric cancer (9,12).
Most mutations of p53 gene or genetic and/
or epigenetic changes of upstream and/or down-
stream located genes in the p53 network result in 
a loss of function of the wild-type gene product. 
However, most but not all mutant p53 proteins 
have a prolonged half-life and accumulate in cells 
(13,14). Both p53 accumulation and its absence 
in the nucleus of malignant cells could thus be 
used as a valuable prognostic marker and predic-
tor of clinical outcome of gastric tumors. Name-
ly, several studies have shown the association of 
p53 mutations with particular histological type 
of gastric cancer, age of the patients at the onset 
of malignancies, and poor response to the treat-
ment (9,14-16).
In the present study, we studied a series of 
230 gastric carcinomas, collected in a period 
from 1983 to 2001. We wanted to combine mo-
lecular genetic analysis data on p53, such as ex-
pression, loss of heterozygosity (LOH), micro-
satellite instability (MSI), and mutational status 
with tumor descriptive characteristics in order 
to discern the value of p53 as a molecular mark-
er for diagnosis and/or prognosis in this type of 
cancer. We showed that at least one of the select-
ed clinical or histopathological features might be 
associated with genetic variables such as p53 ex-
pression, loss of heterozigosity, or microsatel-
lite instability, and could thus in combination 
improve the determination of biological feature 
and/or prognosis of gastric malignancy.
Patients and methods
Patients and samples
We examined 230 primary advanced gastric 
cancers surgically resected at the Department 
of Abdominal Surgery in Ljubljana from 1983-
2001. All patients underwent R0 resection (12). 
One hundred samples, collected from 1983 to 
1992, were formalin-fixed and paraffin-embed-
ded. From 130 samples collected between 1997 
and 2001, portions of tumor tissues and adjacent 
non-tumor mucosa were carefully sampled and 
frozen at -70°C for DNA extraction. In addition, 
their representative portions were again forma-
lin-fixed and paraffin-embedded for immunohis-
tochemistry and histology. Histological evalua-
tion of all samples was confirmed at the Institute 
of Oncology in Ljubljana. The study was ap-
proved by the National Medical Ethics Commit-
tee and informed consent was obtained from all 
participating patients before surgery.
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Most gastric cancer patients were male, with 
1.8:1 male-to-female ratio (Table 1). Mean 
age ± standard deviation (SD) at the operation 
was 61.9 ± 11.3 years. Tumor stage was assessed 
in accordance with the TNM classification sys-
tem (T – size of tumor, N – nodal involve-
ment, M – distant metastasis), and histological 
appearances were categorized according to the 
classifications of Lauren, Ming, and Borrmann 
(5,12,17,18). Cases lost to follow-up (n = 4) 
and those who died within 30 days after surgery 
(n = 5), were excluded from survival analyses.
DNA extraction
DNA was isolated from 100 paraffin sections 
as described previously (19). Briefly, the paraf-
fin-embedded sections were microdissected and 
dewaxed with xylol and ethanol. DNA was ob-
tained from these tissues using the proteinase K-
lysis buffer after 24 hours of incubation at 55°C. 
DNA from 130 freshly frozen tissue samples, 
which were kept at -70°C, was isolated follow-
ing the standard phenol/chloroform protocol. 
Briefly, tissues were incubated overnight at 50°C 
in SDS-proteinase K lytic solution. Afterwards, 
the DNA was extracted with phenol-chloroform 
and precipitated with ethanol. DNA concentra-
tion was measured spectrophotometrically and 
agarose gel electrophoresis was used to confirm 
DNA concentration and integrity.
Analysis of loss of heterozigosity and 
microsatellite instability
Microsatellite loci were examined for loss of het-
erozigosity using the p53 locus microsatellite 
markers p53-1 and p53-2 (20). The loss of het-
erozigosity index was calculated for each paired 
normal and tumor samples using the method de-
scribed by Cawkwell et al (20). In brief, the tu-
mor ratio was divided by the normal ratio, that 
is, T1:T2/N1:N2, where T1 and N1 are the 
peak height of the tumor and the peak height 
of normal samples for the corresponding allele 
1, and T2 and N2 are the peak height of the tu-
mor and the peak height normal samples for the 
corresponding allele 2. The tumors were consid-
ered to have the loss of heterozigosity if the allele 
peak ratio was ≤0.5 or ≥1.5. Tumor samples that 
exhibited novel allele peaks compared with the 
corresponding normal samples were classified as 
having microsatellite instability at that marker 
and were considered uninformative for the loss 
of heterozigosity study. Cases with detectable 
heterozygous alleles and without microsatellite 
instability were defined as informative for loss of 
heterozigosity analysis.
Fluorescence PCR was performed with 1µl 
genomic DNA (25-50 ng), 0.5 µl forward and re-
verse primers (20) for each locus (12.5µM), 5 µl 
dNTPs (2mM), 1.5 µl MgCl2 (25mM), 2.5 µl 
10 × reaction buffer (Gold PCR Buffer, Applied 
Biosystems, Foster City, CA, USA) and 0.5 µl 
of AmpliTaq DNA–polymerase Gold (Applied 
Biosystems) in the final volume of 25 µl. Forward 
primer was 5′ end-labeled with the 6-FAM fluo-
rescent dye (Applied Biosystems). Twenty-two 
cycles of 95°C for 30 seconds, 55°C for 1 min-
Table 1. Clinicopathological features of 230 patients with gastric 
cancer
Parameter No. (%)
Age (years, mean ± standard deviation) 61.9 ± 11.3
Gender (n = 230):
 male 147 (63.7)
 female  83 (36.1)
Lauren’s classification, ref. 5 (n = 230):
 intestinal 126 (54.8)
 diffuse  74 (32.2)
 mixed  30 (13.0)
Borrmann’s classification, ref. 17 (n = 228):
 type 1  27 (11.7)
 type 2  58 (25.4)
 type 3 123 (53.9)
 type 4  20 (8.8)
Ming’s classification, ref. 18 (n = 229):
 expansive  86 (37.6)
 infiltrative 106 (46.3)
 mixed  37 (16.2)
TNM classification, ref. 12 (n = 230):
 I  49 (21.3)
 II  68 (29.6)
 III  77 (33.5)
 IV  36 (15.7)
Tumor location:
 upper  62 (27.0)
 middle  74 (32.2)
 lower  80 (34.8)
 whole  14 (6.1)
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ute, and 72°C for 30 seconds were performed 
with an initial denaturation step at 95°C for 12 
minutes and final extension step at 72°C for 10 
minutes for both fragments. The reactions were 
carried out in a GeneAmp PCR System 9600 
Thermal Cycler (Applied Biosystems). The am-
plified, fluorescently tagged products were then 
diluted with deionized formamide, and 0.5 µl of 
internal standard TAMRA 500 (Applied Biosys-
tems) was added to each solution. The mixture 
was then denatured for 3 minutes at 95°C, fol-
lowed by ice cooling. Finally, the products were 
separated on ABI Prism 310 Genetic Analyzer 
(Applied Biosystems) by capillary electrophoresis 
and results were evaluated with Genescan analy-
sis software (Applied Biosystems).
Mutation analysis of p53
According to Soussi and Beroud (21), the ma-
jority of p53 mutations were located in the ex-
ons 4 and 10. Therefore, p53 mutational analysis 
was carried out on 28 randomly selected samples, 
equally subgrouped in accordance with their loss 
of heterozigosity (LOH) and microsatellite in-
stability status. It was performed by means of 
automated direct sequencing on AbiPrism 310 
(Applied Biosystems) within the exons 4-10 as 
described previously (22). Briefly, prior to se-
quencing, the PCR products were purified with 
the QIAQuick columns (QIAGEN QIAQuick 
PCR Purification Kit). Afterwards, the Ready 
Dye Terminator Cycle Sequencing Kit (Applied 
Biosystems) was used according to manufactur-
er’s instructions. The sequences of primers were 
selected according to Chang et al (23). Samples 
were grouped into four groups according to their 
microsatellite instability/loss of heterozigosi-
ty status: microsatellite instability (MSI); loss of 
heterozigosity-high (LOH-H) – with loss of het-
erozigosity at both p53 loci; loss of heterozigos-
ity-low (LOH-L) – with loss of heterozigosity at 
only one locus; and no loss of heterozigosity (no-
LOH).
Immunohistochemistry
Paraffin-embedded tumor and non-tumor tis-
sue sections from all 230 patients were immu-
no-stained with a monoclonal mouse antibody 
DO-7 (DAKO, Carpinteria, CA, USA) against 
p53 at a working concentration of 1:500. This 
antibody reacts with both wild-type and mutant 
forms of the p53 protein. Tissue sections were 
deparaffinized and hydrated through a graded se-
ries of alcohols. The immunohistochemistry was 
performed using an automated staining device 
TechMate 500 (DAKO Corp., Glostrup, Den-
mark) after an antigen retrieval process with mi-
crowave treatment (15-minute, 850 W). Follow-
ing the completed automated staining procedure 
with labeled streptavidin-biotin system meth-
od using peroxidase/DAB (3,3′-diaminobenzi-
dine tetrahydrochloride) as the reaction indica-
tor (DAKO ChemMate K5001), the nuclear 
counterstaining was accomplished with light he-
matoxylin. Positive and negative controls were 
included with each staining series. Negative con-
trols were obtained by omission of the primary 
antibody. A set of breast cancers with high lev-
els of p53 was used as positive control. Two in-
dependent pathologists assessed the results of 
immunohistochemical staining. For statistical 
analysis, the results were considered to be posi-
tive for p53 (p53+), if 25% or more of the nuclei 
of neoplastic cells were stained.
Statistical analysis
The distribution of each clinicopathologi-
cal and genetic variable was calculated by the 
χ2 test. Statistical significance was defined as 
P<.05. Survival was assessed by the Kaplan-
Meier method and differences between groups 
were evaluated using the log-rank test. Mul-
tivariate survival analyses were further per-
formed using the Cox proportional-hazards 
regression model. In the Cox multivariate anal-
yses, forward stepwise procedure was used to 
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determine the predictor variables. Only the 
variables that resulted in P values <0.05 in the 
Kaplan-Meier test were entered into the Cox 
proportional hazard model for the determina-
tion of independent prognostic factors for gas-
tric cancer. The postoperative period was mea-
sured from the date of surgery to the date of the 
last follow-up or death.
Results
Microsatellite instability and loss of heterozigosity 
evaluation
Microsatellite instability status was determined 
for 173 patients out of 230 included in this study. 
Fifty-seven cases were excluded due to inappro-
priate quality of DNA. Microsatellite instability 
at the examined loci was assessed separately with 
relevance to selected clinicopathological variables 
(Table 2). Seventeen (9.8%) patients had micro-
satellite instability at either p53-1 or p53-2 lo-
cus and 156 (90.2%) had no microsatellite insta-
bility. The majority of microsatellite instability 
was found at locus p53-1, while only three in-
cidences were found at p53-2, with two of them 
occurring simultaneously with microsatellite 
instability at p53-1. Microsatellite instability 
groups showed clear association with gender, 
TNM stage, and pN. Higher percentage of mi-
crosatellite instability was associated with TNM 
stages I and II (Table 2).
Table 2. Statistical comparison between clinicopathological fea-
tures and microsatellite instability (MSI) in Slovenian patients 
with gastric cancer*
Clinicopathological
characteristics Total No MSI MSI P
Total 156 17
Gender:
 male 109 103  6 0.017†
 female  64  53 11
Borrmann’s classification (ref 17):
 I  22  19  3 0.058‡
 II  41  33  8
 III  96  90  6
 IV  13  13  0
Lauren’s classification (ref 5):
 intestinal  99  88 11 0.505†
 diffuse  58  52  6
 mixed  16  16  0
Ming’s classification (ref 18):
 expansive  76  64 12 0.052‡
 infiltrative  80  75  5
 mixed  16  16  0
TNM classification (ref 12):
 I  42  34  8 0.006§
 II  55  49  6
 III  52  49  3
 IV  24  24  0
pT:
 T1   4   2  2 0.100§
 T2  80  72  8
 T3  84  77  7
 T4   5   5  0
pN:
 N0  70  58 12 0.004§
 N1  62  57  5
 N2  26  26  0
 N3  15  15  0
pM:
 M0 162 145 17 0.604†
 M1  11  11  0





Table 3. Statistical comparison between clinicopathological 
characteristics and overall loss of (LOH) heterozigosity status 
of the p53 gene in selected gastric cancer cases*
Clinicopathological 
characteristics Total LOH-L LOH-H No-LOH P
Total 83 31 10 42
Gender:
 male 54 23  6 25  0.393†
 female 29  8  4 17
Borrmann’s classification (ref 17):
 I  9  6  1  2  0.478‡
 II 21  9  3  9
 III 45 14  5 26
 IV  8  2  1  5
Lauren’s classification (ref 5):
 intestinal 49 22  9 18  0.004†
 diffuse 27  6  0 21
 mixed  7  3  1  3
Ming’s classification (ref 18):
 expansive 40 22  8 10 <0.001†
 infiltrative 37  7  2 28
 mixed  6  2  0  4
pT:
 T1  1  0  0  1  0.746§
 T2 41 16  6 19
 T3 39 13  4 22
 T4  2  2  0  0
pN:
 N0 30 10  2 18  0.848§
 N1 29 14  4 11
 N2 13  3  2  8
 N3 11  4  2  5
pM:
 M0 77 29  9 39 >0.950†
 M1  6  2  1  3
p53 expression║
 – 60 19  6 35  0.075‡
 + 23 12  4  7
*Abbreviations: LOH-L – LOH-low; LOH-H – LOH-high; pT – size of the tumor; pN 




IIMinus  – no detectable p53 expression; plus – p53 overexpression.
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The loss of heterozigosity analysis was per-
formed for 170 samples out of 230 patients who 
underwent total gastrectomy, while the remain-
ing 60 cases were excluded due to inappropriate 
quality of DNA. Markers with detectable hetero-
zygous alleles were defined as informative, so 115 
and 98 informative individuals, with loss of het-
erozigosity at p53-1 or p53-2 marker, respective-
ly, were included in the analysis (Tables 3 and 4). 
Twenty-four tumors (20.9%, 24/115) exhibit-
ed loss of heterozigosity at p53-1 and 27 (27.6%, 
27/98) at p53-2 locus. Only 10 (15.6%, 10/64) 
individuals had loss of heterozigosity at both loci. 
There were no differences in the distribution of 
gender, size of the tumor (pT), pN, presence of 
distant metastases (pM), Borrmann’s classifica-
tion, or TNM stage between the selected groups 
(Table 3). However, there was a clear association 
between Lauren’s and Ming’s classification and 
loss of heterozigosity groups (Table 3). Next, we 
analyzed loss of heterozigosity at both p53 loci 
separately (Table 4). We found a trend between 
p53 expression and p53-1 LOH, while there was 
no association between this variable and p53-2 
LOH. However, both loci showed association 
with Lauren’s and Ming’s classification. No oth-
er associations were found with p53 markers and 
clinicopathological parameters.
P53 expression
In the present series, 66 (28.7%) cases showed 
positive p53 expression and 164 (71.3%) were 
categorized negative. p53 expression was inverse-
ly associated with pM (Table 5). No other sig-
Table 4. Statistical comparison between clinicopathological parameters and separate p53-1 or p53-2 LOH status in selected gastric 
cancer cases*
Clinicopathological characteristics Total P53-1 LOH No-LOH P Total P53-2 LOH No-LOH P
Total 115 24 91 98 27 71
Gender:
 male  77 15 62 0.631† 61 20 41  0.166†
 female  38  9 29 37  7 30
Borrmann’s classification (ref 17):
 I  10  2  8 0.305‡ 11  6  5  0.191‡
 II  27  9 18 26  6 20
 III  64 10 54 55 14 41
 IV  13  3 10  6  1  5
Lauren’s classification (ref 5):
 intestinal  60 18 42 0.003† 56 22 34  0.010†
 diffuse  42  2 40 35  4 31
 mixed  13  4  9  7  1  6
Ming’s classification (ref 18):
 expansive  42 16 26 0.002† 44 22 22 <0.001†
 infiltrative  62  6 56 46  5 41
 mixed  10  2  8  8  0  8
pT:
 T1   2  0  2 0.792§  2  0  2  0.474§
 T2  56 13 43 45 15 30
 T3  53  9 44 50 12 38
 T4   4  2  2  1  0  1
pN:
 N0  40  6 34 0.060§ 42  8 34  0.633§
 N1  42  8 34 32 14 20
 N2  18  4 14 13  3 10
 N3  15  6  9  9  2  7
pM:
 M0 106 21 85 0.392† 93 26 67 >0.950
 M1   9  3  6 (6.6)  5  1  4
P53 expression:
 –  89 14 75 0.012‡ 73 17 56  0.106‡
 +  26 10 16 25 10 15
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nificant relations were apparent between p53 ex-
pression and clinicopathological parameters.
Mutation analysis
p53 mutation analysis was performed on 28 gas-
tric cancer samples, equally distributed to the 4 
groups in accordance with the microsatellite in-
stability/loss of heterozigosity status. All nucleo-
tide changes were checked against IARC TP53 
Mutation Database and p53 Web Site (http://
p53.free.fr). Table 6 shows the results of muta-
tional analysis for 2 out of 6 cases with MSI+and 
13 out of 22 cases with microsatellite instabili-
ty negative status. In 15 (53.6%) cases we found 
a mutated p53 sequence. Altogether, we found 
7 changes and some cases harbored more than 1 
change. Five patients had 2 or 3 sequence chang-
es, while the rest of them had only 1. Regarding 
the distribution of mutations among patients, 
there were 20 heterozygous and 3 homozygous 
changes. Some individuals had more than one 
change. There was no significant association be-
tween clinicopathological parameters and muta-
tional status of p53 gene. Also, we did not find 
significant association of these nucleotide chang-
es with p53 expression. Only three cases harbor-
ing nucleotide changes had positive p53 expres-
sion. Of 7 nucleotide changes found, there were 
3 silent (P36P, R213R and R280R), 1 missense 
(R282R), 1 frameshift (F134na), and 1 splice 
(IVS-4(11934_11958)ins) mutation. Patient 
(case 140) with R282R mutation showed p53 
overexpression as well, while the other 2 in the 
group with positive p53 expression harbored si-
lent mutations (cases 143 and 154).
Survival analysis
At the end of the follow-up period, 68 of 221 
(30.8%) patients were still alive. Nine patients 
were excluded, 4 cases were lost to follow up and 
5 died within 30 days after surgery. The over-
all 5-year survival was 43.1%. Univariate sur-
vival analysis showed that p53 expression, Bor-
rmann’s classification, pT, pN, pM, TNM stage, 
grade, and tumor location were significant prog-
nostic factors (P<.05) (Table 7). High p53 ex-
pression, presence of metastases, higher nodal in-
volvement, higher TNM stage, higher grade, and 
tumor invasion predicted shorter 5-year survival 
(Figure 1). Microsatellite instability and loss of 
heterozigosity status had no prognostic signifi-
cance for survival in the whole group. Multivari-
ate analyses were performed for 216 patients that 
were accompanied with complete data sets (Ta-
ble 8). Cox regression model included all signifi-
cant variables (p53 expression, Borrmann’s clas-
sification, pT, pN, pM, TNM stage, grade and 
tumor location). The forward stepwise method 
showed that the only independent predictors of 
shorter survival were p53 expression and TNM 
stage.
Table 5. Statistical comparison between clinicopathological 
factors and p53 expression in gastric carcinomas of Slovenian 
patients*
Clinicopathological Number P53 expression
characteristics of patients – + P
Total 164 66
Gender
 male 147 102 45 0.392†
 female  83  62 21
Borrmann’s classification (ref 17):
 I  27  19  8 0.874†
 II  58  39 19
 III 123  90 33
 IV  20  14  6
Lauren’s classification (ref 5):
 intestinal 126  87 39 0.703†
 diffuse  74  55 19
 mixed  30  22  8
Ming’s classification (ref 18):
 expansive  89  56 30 0.087†
 infiltrative 106  83 23
 mixed  37  24 13
pT:
 T1   5   5  0 0.520‡
 T2 105  75 30
 T3 115  80 35
 T4   5   4  1
pN:
 N0  81  61 20 0.120‡
 N1  80  62 18
 N2  42  21 21
 N3  27  20  7
pM:
 M0 216 158 58 0.028§
 M1  14   6  8
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Discussion
Our study showed that gastric cancers with loss 
of heterozigosity at different p53 loci, displayed 
significant association with the most frequent-
ly used classifications in clinical practice, Lau-
ren’s and Ming’s classification (5,18). Statistical 
analyses showed that more patients with LOH-
low and LOH-high status had intestinal type of 
gastric cancer, compared with patients without 
loss of heterozigosity at p53. On the other hand, 
more patients with diffuse gastric cancer type 
had no loss of heterozigosity at the examined 
p53 loci. This is in accordance with some previ-
ous studies (10,24).
However, in general reports regarding mic-
rosatellite instability and loss of heterozygosity, 
genotypes in gastric cancers are more or less con-
flicting, displaying the variation of microsatellite 
instability in gastric cancer among different stud-
ies (10). It is widely accepted that tumors with 
microsatellite instability phenotypes have lower 
frequency of loss of heterozigosity and lower rate 
of mutations. This suggests that there are at least 
two pathways, mutator and suppressor, which 
could be independent of each other at least in 
the early stages of gastric cancer development 
(10). Nevertheless, several studies showed cer-
tain overlap between these two pathways (25). In 
our sample group, we found relatively low level 
of microsatellite instability (7.4%), probably be-
cause this type of genetic abnormality was detect-
ed at loci for p53 gene, initially selected for the 
analysis of loss of heterozigosity. On the other 
hand, reported variations of microsatellite insta-
bility in gastric cancer range from 9 to 44%, and 
some researchers have already proposed the use 
of alternative markers for microsatellite instabil-
ity assessment (26). However, our microsatellite 
instability analyses revealed a clear trend of de-
creasing percentage of microsatellite instability 
with an increase in TNM stage, which is in ac-
cordance with previous studies (27).
Overexpression of p53 in gastric cancer tis-
sues ranges from 13 to 54%, which is compara-
ble with 28.7%, as found in our study (28). Sev-
Table 6. p53 mutations and LOH status at p53 locus in Slovenian patients with gastric cancer*
Patient Exon Nucleotide change Protein change Effect LOH status
MSI
 151 4 g.12032G>A† p.P36P silent Un
4 g.12139C>G† p.P72R polymorphism
Intron 3 IVS-4(11934_11958)dup† splice
 162 4 g.12139C>G§ p.P72R polymorphism Un
Intron 3 IVS-4(11934_11958)dup§ splice
No MSI
 121 5 g.13079delT‡ p.F134na frameshift LOH-L
 140 8 g.14513C>T‡ p.R282W missense LOH-H
 142 4 g.12139C>G‡ p.P72R polymorphism Un
Intron 3 g.14513C>T§ p.R282W missense
Intron 3 IVS-4(11934_11958)dup† splice
 147 4 g.12139C>G† p.P72R polymorphism No-LOH
 153 6 g.13399A>G† p.R213R silent No-LOH
 154 8 g.14509A>G† p.R280R silent LOH-L
 164 4 g.12139C>G† p.P72R polymorphism Un
Intron 3 IVS-4(11934_11958)dup† splice
 160 6 g.13399A>G† p.R213R silent LOH-L
 169 4 g.12032G>A† p.P36P silent No-LOH
 171 4 g.12032G>A§ p.P36P silent No-LOH
4 g.12139CG† p.P72R polymorphism
 173 4 g.12139C>G† p.P72R polymorphism No-LOH
 174 4 g.12139C>G† p.P72R polymorphism Un
 175 4 g.12139C>G† p.P72R polymorphism No-LOH
Intron 3 IVS-4(11934_11958)dup† splice
*Abbreviations: Un – unstable, MSI at either one or both loci; LOH-L – LOH-low; LOH-H – LOH-high.
†Somatic, heterozygous nucleotide change.
‡Nucleotide change only in tumor tissue, heterozygous.
§Somatic nucleotide change, homozygous.
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eral studies reported no significant relationship 
between p53 positivity and macroscopic appear-
ance, histological classifications, and growth pat-
tern (29). Similarly, our study also showed no 
significant relationship between these parame-
ters. It was postulated that p53 overexpression 
and mutations were an early event, critical in 
the development of differentiated carcinomas. 
In this respect, the frequent detection of these 
changes in undifferentiated carcinomas could be 
due to frequent conversion of differentiated tu-
mors to the undifferentiated ones as the disease 
progresses (10). This could explain the discrepan-
cy between histological parameters and p53 ex-
pression found in our study, since almost all cases 
were diagnosed with an advanced gastric cancer.
The p53 mutational status did not result in a 
clear association with p53 expression, which is in 
accordance with several studies (27,30). It is well 
known that certain types of mutations do not 
produce stable proteins and that protein over-
expression could be the result of stress environ-
ment in stomach, which is why even the mini-
mal accumulation of wild-type protein could 
be detected by sensitive immunohistochemical 
methods (14,31). In our study, we found p53 
nucleotide changes in half of the examined cas-
es and, although we selected a small group of pa-
tients for mutation analysis, this prevalence fell 
within the wide range of p53 mutation preva-
Table 7. Univariate survival analysis of clinicopathological vari-
ables in gastric cancer patients*
Variable 5-y survival (%) P
P53 expression:
 –  47.4  0.033
 +  31.9
Borrmann’s classification (ref 17):
 type 1  55.6  0.014
 type 2  52.7
 type 3  40.7
 type 4  12.5
Lauren’s classification (ref 5):
 intestinal  46.9  0.129
 diffuse  40.6
 mixed  34.1
Ming’s classification type (ref 18):
 expansive  48.8  0.496
 infiltrative  38.4
 mixed  42.9
pT:
 T1 100 <0.001
 T2  57.6
 T3  28.6
 T4  20.0
pN:
 N0  74.6 <0.001
 N1  37.2
 N2  12.0
 N3   3.8
pM:
 M0  44.9 <0.001
 M1   9.1
TNM:†
 I  82.8 <0.001
 II  53.2
 III  25.2
 IV   3.0
Grade:
 G1  79.3  0.032
 G2  42.2
 G3  39.3
 G4  35.7
Location:
 upper  27.3  0.002
 middle  51.9
 lower  49.1
 whole  30.8
*Abbreviations: pT – size of the tumor; pN – involvement of lymph nodes; pM – distant 
metastasis.
†TNM classification of gastric tumors tumors (12).
Table 8. Multivariate survival analysis of clinicopathological 
variables in gastric cancer patients*
Category B† HR (95% CI) P
P53 expression:
 – -0.401 0.669 (0.470-0.953)  0.026
 + Reference
TNM classification (ref 12):
 I -2.620 0.73 (0.039-0.137) <0.001
 II -1.970 0.139 (0.083-0.233) <0.001
 III -0.886 0.412 (0.265-0.641) <0.001
 IV Reference
*Abbreviations: HR – hazard ratio, relative risk; CI – 95% confidence interval.
†Predicted change in the hazard for a unit increase in the predictor.
Figure 1. Survival of patients according to p53 expression (from sur-
gery to the last follow-up).
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lence (8 to 65%) found in previous studies (19). 
The P72R polymorphism was relatively frequent 
in our group and was previously associated with 
an increased risk of developing cancers of the 
lung, stomach, esophagus, and the cervix (32). 
Although our sample was too small to perform 
statistical analysis of haplotypes, our finding 
supports the findings of previous studies, show-
ing arginine allele to be more efficient in apop-
tosis in cell cultures (16). It was concluded that 
these polymorphisms could influence the occur-
rence or progression of cancer (16). The biologi-
cal activity of insertion of 16 base pairs in intron 
3 and deletion of one nucleotide in codon 134 
have not been tested and it has been assumed 
that frameshift and nonsense mutations are del-
eterious for p53 (http://p53.free.fr, ref. 33). One 
patient had missense R282W mutation and this 
change was associated with the loss of transacti-
vation and the loss of dominant negative nature, 
because it had no effect on transactivational ac-
tivity of the wild-type p53 gene product in re-
porter assays (34). This and loss of heterozigosi-
ty, found in this case, could explain the absence 
of p53 immunostaining. In conclusion, although 
performed on a small sample, our results indicate 
that p53 positivity in gastric tumors is not an in-
dicator of p53 mutations. Several other studies 
also confirmed this assumption (13,19,33). Even 
more, because of the biological variability of p53 
mutations and the diverse causes of p53 protein 
accumulation, either parameter alone may fail to 
predict the prognosis correctly (13).
Today, the only prognostic factors accept-
ed in clinical practice are clinicopathological fea-
tures, such as TNM stage, age, or macroscopic tu-
mor type (27). Univariate survival analyses of our 
group of patients also revealed TNM stage, pT, 
pN, pM, grade, and Borrmann’s classification as 
significant factors for predicting survival. We also 
found positive p53 expression associated with 
poorer survival (Figure 1). On the other hand, al-
though the role of p53 expression and its genetic 
changes in determining the therapy outcome has 
been studied in many different tumor types, the 
results are still conflicting (32). Some research-
ers showed that, in gastric carcinoma, p53 over-
expression was associated with a lack of response 
to chemotherapy, while a few others showed that 
p53 absence is the predictor of poorer outcome 
(14,27,32). However, in the Western countries 
it was generally accepted that positive p53 ex-
pression had a poor prognosis outcome (28). The 
multivariate analysis showed TNM stage and 
p53 expression as independent prognostic factors 
for our group of gastric cancers. Although previ-
ous studies showed these two parameters to be 
important for survival, with genome-wide meth-
ods, such as microarrays, chromosomal compar-
ative genomic hybridization, methylation assays, 
and single nucleotide polymorphisms, new views 
were opened up on complexity of gastric cancers 
(10,26,27,35,36).
In conclusion, our findings revealed that the 
combination of immunohistochemistry and 
detecting genetic changes of p53, followed by 
search of their association, in particular instanc-
es could be of value for predicting the behavior of 
gastric tumors.
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